Can a Blood-Clot drug tame severe COVID-19?

NCT ID NCT04652115

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a drug called defibrotide is safe and feasible for people with severe COVID-19 pneumonia. About 42 adults with confirmed COVID-19 and lung infiltrates will receive the drug intravenously. Researchers will monitor for bleeding and low blood pressure as key safety concerns.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Defibrotide (given intravenously)

What this could lead to

If it works, this could point toward a new treatment to reduce complications in severe COVID-19 pneumonia.

What could go wrong

This is a small, early-phase safety study with only 42 participants, so it may not prove effectiveness. There are also risks of bleeding and low blood pressure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02214, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact